VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly

Leukemia and Lymphoma

Volumn 48, Issue 11, 2007, Pages 2167-2171

  Fina, Mariapaola ^a   Tani, Monica ^a   Stefoni, Vittorio ^a   Musuraca, Gerardo ^a   Marchi, Enrica ^a   Pellegrini, Cinzia ^a   Alinari, Lapo ^a   Derenzini, Enrico ^a   Bacci, Francesco ^a   Pileri, Stefano ^a   Baccarani, Michele ^a   Zinzani, Pier Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

DLBCL; Elderly; VNCOP B plus rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MALE; NEUTROPENIA; OVERALL SURVIVAL; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; RESPONSE TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 36049040751     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701642102     Document Type: Article

References (19)

1. Sonneveld, P. and Michiels, J. J. (1990) Full-dose chemotherapy in elderly patients with non-Hodgkin lymphoma. A feasibility study using a mitoxantrone-containing regimen. Br J Cancer, 62, pp. 105-108.
2. Tirelli, U., Zagonel, V., Errante, D., Serraino, D., Talamini, R., De Cicco, M. and Carbone, A. (1992) A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J Clin Oncol, 10, pp. 228-236.
3. O'Reilly, S. E., Klimo, P. and Connors, J. M. (1991) Low dose ACOP-B and VABE. Weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol, 9, pp. 741-747.
4. Martelli, M., Guglielmi, C., Coluzzi, S., Avvisati, G., Amadori, S. and Giovannini, M. (1993) P-VABEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol, 11, pp. 2362-2369.
5. Bertini, M., Freilone, R., Vitolo, U., Botto, B., Pizzuti, M. and Gavarotti, P. (1994) P-VEBEC: A new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol, 5, pp. 895-900.
6. Armitage, J. O., Dick, F. R., Corder, M. P., Garneau, S. C., Platz, C. E. and Slymen, D. J. (1982) Predicting therapeutic outcome in patients with diffuse histiocitic lymphoma treated with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). Cancer, 50, pp. 1695-1702.
7. Vose, J. M., Armitage, J. O., Weisemburger, D. D., Bierman, P. J., Sorensen, S. and Hutcins, M. (1988) The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol, 6, pp. 1838-1844.
8. Zinzani, P. L., Bendandi, M., Gherlinzoni, F., Mazza, P., Salvucci, M. and Aitini, E. (1993) VNCOP-B regimen in the treatment of high grade non-Hodgkin's lymphoma in the elderly. Hematologica, 78, pp. 378-382.
9. Zinzani, P. L., Pavone, E., Storti, S., Moretti, L., Fattori, P. P. and Guardigni, L. (1997) Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high grade non-Hodgkin's lymphoma. Blood, 89, pp. 3974-3979.
10. Zinzani, P. L., Storti, S., Zaccaria, A., Moretti, L., Magagnoli, M. and Pavone, E. (1999) Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood, 94, pp. 33-38.
11. Zinzani, P. L., Gherlinzoni, F., Storti, S., Zaccaria, A., Pavone, E. and De Renzo, A. (2002) Randomized trial of 8-week versus 12-week NCOP-B plus G-CSF regimes as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol, 13, pp. 1364-1369.
12. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. and Buoabdallah, R. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse late B-cell lymphoma. N Eng J Med, 346, pp. 235-242.
13. Freugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R. and Fermé, C. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 23, pp. 4117-4126.
14. Pfeundschuh, M. G., Kloess, M., Zeylanova, S., Lengfelder, E., Franke, A. and Reiser, M. (2006) Six vs eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large-B cell lymphoma (DLBCL). Results of the completed RICOVER-60 trial of the German High Grade non-Hodgkin lymphoma Study Group (DSHNHL). Blood (Suppl.), 108, p. 205A.
15. Harris, N. L., Jaffe, E. S., Dielbod, J., Flandrin, G., Muller-Hermelink, H. K. and Vardiman, J. (1999) World Health organization classification of neoplastic disease of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting. Airlie House, Virginia, November 1997. J Clin Oncol, 17, pp. 3835-3849.
16. Carbone, P. P., Kaplan, H. S. and Musshoff, K. (1971) Report of the committee on Hodgkin's disease staging classifications. Cancer Res, 31, pp. 1860-1861.
17. Klimo, P. and Connors, J. M. (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med, 102, pp. 596-602.
18. Cheson, B. D., Horning, J. S., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connor, J. M. (1999) Report of international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol, 17, pp. 1244-1253.
19. Kaplan, E. L. and Meier, P. (1958) Non-parametric estimation from incomplete observations. JAMA, 53, pp. 457-481.